华润医药(03320.HK) 公布，集团旗下上海长征富民金山制药收到国家药监局通知，其腹膜透析液(乳酸盐-G1.5%)及腹膜透析液(乳酸盐-G2.5%)获颁发《药品补充申请批准通知书》。
腹膜透析液(乳酸盐)主要适用于因非透析治疗无效，需要连续不卧床性腹膜透析治疗的急性及慢性肾功能衰竭患者。集团表示，获发药品补充申请批准通知书，是对该产品规格的进一步补充，有利于发挥该系列药品未来市场销售和市场竞争的潜力，进一步丰富华润医药产品线。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-09-11 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.